CITIUS ONCOLOGY, INC.

Citius Oncology, Inc., trading on Nasdaq under the ticker TENK, filed an 8-K current report with the Securities and Exchange Commission on August 16, 2024, in connection with its business combination with TenX Keane Acquisition Corp, a healthcare-focused blank-check company that completed its initial public offering in 2022. The SPAC was sponsored by TenX Keane Capital LLC and targeted the oncology and specialty pharmaceutical sector. The combined company, Citius Oncology, was spun off from Citius Pharmaceuticals prior to the transaction and focuses on cancer therapeutics. Sign up at SpacDesk for complete filing history, sponsor profiles, and deal analytics across the full SPAC universe.